Mortality associated with third-generation cephalosporin resistance in Enterobacterales bloodstream infections at eight sub-Saharan African hospitals (MBIRA): a prospective cohort study - 26/10/23
, Andrea M Rehman, PhD a, Marlieke E A de Kraker, PhD b, Lola Madrid, PhD a, c, Meron Kebede, MD c, Appiah-Korang Labi, PhD d, Noah Obeng-Nkrumah, PhD e, Brian Nyamwaya, MSc f, Eunice Kagucia, PhD f, Derek Cocker, PhD g, i, j, Kondwani Kawaza, FCP h, Rebecca Lester, PhD g, j, Kenneth C Iregbu, MD k, Nubwa Medugu, MSc k, l, Philip I Nwajiobi-Princewill, MSc k, Angela Dramowski, PhD m, Tolbert Sonda, PhD p, Asia Hemed, MD p, Sombo Fwoloshi, MMed q, David Ojok, MSc r, J Anthony G Scott, ProfFRCP a, Andrew Whitelaw, ProfMSc n, ofor the
MBIRA study collaborators†
Summary |
Background |
Bacteria of the order Enterobacterales are common pathogens causing bloodstream infections in sub-Saharan Africa and are frequently resistant to third-generation cephalosporin antibiotics. Although third-generation cephalosporin resistance is believed to lead to adverse outcomes, this relationship is difficult to quantify and has rarely been studied in this region. We aimed to measure the effects associated with resistance to third-generation cephalosporins in hospitalised patients with Enterobacterales bloodstream infection in Africa.
Methods |
We conducted a prospective, matched, parallel cohort study at eight hospitals across sub-Saharan Africa. We recruited consecutive patients of all age groups with laboratory-confirmed Enterobacterales bloodstream infection and matched them to at least one patient without bloodstream infection on the basis of age group, hospital ward, and admission date. Date of infection onset (and enrolment) was defined as the day of blood sample collection for culturing. Patients infected with bacteria with a cefotaxime minimum inhibitory concentration of 1 mg/L or lower were included in the third-generation cephalosporin-susceptible (3GC-S) cohort, and the remainder were included in the third-generation cephalosporin-resistant (3GC-R) cohort. The primary outcomes were in-hospital death and death within 30 days of enrolment. We used adjusted multivariable regression models to first compare patients with bloodstream infection against matched patients within the 3GC-S and 3GC-R cohorts, then compared estimates between cohorts.
Findings |
Between Nov 1, 2020, and Jan 31, 2022, we recruited 878 patients with Enterobacterales bloodstream infection (221 [25·2%] to the 3GC-S cohort and 657 [74·8%] to the 3GC-R cohort) and 1634 matched patients (420 [25·7%] and 1214 [74·3%], respectively). 502 (57·2%) bloodstream infections occurred in neonates and infants (age 0–364 days). Klebsiella pneumoniae (393 [44·8%] infections) and Escherichia coli (224 [25·5%] infections) were the most common Enterobacterales species identified. The proportion of patients who died in hospital was higher in patients with bloodstream infection than in matched controls in the 3GC-S cohort (62 [28·1%] of 221 vs 22 [5·2%] of 420; cause-specific hazard ratio 6·79 [95% CI 4·06–11·37] from Cox model) and the 3GC-R cohort (244 [37·1%] of 657 vs 115 [9·5%] of 1214; 5·01 [3·96–6·32]). The ratio of these cause-specific hazard ratios showed no significant difference in risk of in-hospital death in the 3GC-R cohort versus the 3GC-S cohort (0·74 [0·42–1·30]). The ratio of relative risk of death within 30 days (0·82 [95% CI 0·53–1·27]) also indicated no difference between the cohorts.
Interpretation |
Patients with bloodstream infections with Enterobacterales bacteria either resistant or susceptible to third-generation cephalosporins had increased mortality compared with uninfected matched patients, with no differential effect related to third-generation cephalosporin-resistance status. However, this finding does not account for time to appropriate antibiotic treatment, which remains clinically important to optimise. Measures to prevent transmission of Enterobacterales could reduce bloodstream infection-associated mortality from both drug-resistant and drug-susceptible bacterial strains in Africa.
Funding |
Bill & Melinda Gates Foundation.
Le texte complet de cet article est disponible en PDF.Plan
Vol 23 - N° 11
P. 1280-1290 - novembre 2023 Retour au numéro
Article précédent
- Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial
- Issaka Sagara, Sara A Healy, Mahamadoun H Assadou, Mamady Kone, Bruce J Swihart, Jennifer L Kwan, Jonathan Fintzi, Kourane Sissoko, Bourama Kamate, Yacouba Samake, Merepen A Guindo, M’Bouye Doucoure, Karamoko Niaré, Amagana Dolo, Balla Diarra, Kelly M Rausch, David L Narum, David S Jones, Nicholas J MacDonald, Daming Zhu, J Patrick Gorres, Alemush Imeru, Rathy Mohan, Ismaila Thera, Irfan Zaidi, Fernando Salazar-Miralles, Junhui Duan, Jillian Neal, Robert D Morrison, Olga Muratova, Daman Sylla, Elise M O’Connell, Yimin Wu, Jen C C Hume, Mamadou B Coulibaly, Charles F Anderson, Sekou F Traore, Ogobara K Doumbo, Patrick E Duffy
- Population immunity to pneumococcal serotypes in Kilifi, Kenya, before and 6 years after the introduction of PCV10 with a catch-up campaign: an observational study of cross-sectional serosurveys
- Katherine E Gallagher, Ifedayo M O Adetifa, Caroline Mburu, Christian Bottomley, Donald Akech, Angela Karani, Emma Pearce, Yanyun Wang, E Wangeci Kagucia, David Goldblatt, Laura L Hammitt, J Anthony G Scott
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?